TCGX Acquisition Corp. (TCGX) is a Blank Checks company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for TCGX, including 3 SEC filings and 2 offerings. The most recent was published Nov 9, 2026.
News · 26 weeks5+100%
2026-05-172026-11-08
Mix590d
- SEC Filings3(60%)
- Offering2(40%)
Activity · 52 weeks52 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
5 items- SECSEC Form 10-Q filed by TCGX Acquisition Corp.10-Q - TCGX Acquisition Corp. (0002137965) (Filer)
- SECSEC Form 425 filed by TCGX Acquisition Corp.425 - TCGX Acquisition Corp. (0002137965) (Subject)
- PRTriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of DirectorsTriGemX Bio, Inc. ("TriGemX Bio"), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (NASDAQ:TCGX) ("TCGX"), a publicly listed special purpose acquisition company, today announced that Daniel Lynch has been appointed Chairman of the TriGemX Bio Board of Directors (the "Board"). Mr. Lynch will remain Chairman of the Board following the closing of the previously announced proposed business combination between TriGemX Bio and TCGX. "We are delighted to welcome Dan to our Board of Directors, and I am thrilled to be working with him once again," said Jeff Goater, CEO of TriGemX Bio. "Dan is one of the preemin
- SECSEC Form 425 filed by TCGX Acquisition Corp.425 - TCGX Acquisition Corp. (0002137965) (Subject)
- PRTriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business CombinationTriGemX Bio, Inc. ("TriGemX Bio"), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (NASDAQ:TCGX) ("TCGX"), a publicly listed special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") to the U.S. Securities and Exchange Commission ("SEC"). The submission of the Registration Statement marks an important milestone toward the completion of the previously announced proposed business combination between TriGemX Bio and TCGX that would result in TriGemX Bio becoming a publicly traded company listed on Nasdaq un
TCGX FAQ
6 questionsWhat is the latest news on TCGX?
In the last 30 days Quantisnow tracked 5 wire items for TCGX: 3 SEC filings and 2 offerings. The most recent was published on November 9, 2026.Where does TCGX stock trade?
TCGX Acquisition Corp. (TCGX) is listed on NASDAQ.What sector and industry is TCGX in?
TCGX Acquisition Corp. operates in the Finance sector, Blank Checks industry.When did TCGX Acquisition Corp. go public?
TCGX Acquisition Corp. (TCGX) completed its IPO in 2026.What companies are similar to TCGX?
Notable peers in the same industry include PRE (Prenetics Global Limited), OXSQ (Oxford Square Capital Corp.), INV (Innventure Inc.), ILLU (Illumination Acquisition Corp I), TACO (Berto Acquisition Corp.). Compare TCGX side-by-side with any of them on Quantisnow.How can I track TCGX on Quantisnow?
Quantisnow aggregates TCGX Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TCGX to receive live email and push alerts on every new disclosure.